Literature DB >> 28188632

Tic, Triggering, and Tearing: From CTN to SUNHA.

R Benoliel1, Y Sharav2, Y Haviv2, G Almoznino2,3.   

Abstract

PREMISE: Classical trigeminal neuralgia (CTN) and the short-lasting unilateral neuralgiform headache attacks (SUNHA) are clinically similar. PROBLEM: The SUNHAs include short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA). Shared clinical signs with CTN include severe, unilateral trigeminal pain that is often triggered by innocuous stimuli and accompanied by a dull persistent background pain. Recent reports on trigeminal neuralgia cases with atypical features such as autonomic signs and prolonged attack duration further blur the clinical distinction between CTN and SUNHAs. POTENTIAL SOLUTIONS: Are the similarities greater than their differences? If so, this may reflect a spectrum of disease ranging from typical CTN attacks to typical SUNHAs with a mixed phenotype in the middle. In this review they will summarize the overlap between these entities and contrast the pathophysiology and treatment approach.
© 2017 American Headache Society.

Entities:  

Keywords:  CTN; SUNHA; trigeminal neuralgia

Mesh:

Year:  2017        PMID: 28188632     DOI: 10.1111/head.13040

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  3 in total

Review 1.  SUNCT and SUNA: an Update and Review.

Authors:  Karissa N Arca; Rashmi B Halker Singh
Journal:  Curr Pain Headache Rep       Date:  2018-06-21

Review 2.  Postherpetic Neuralgia and Trigeminal Neuralgia.

Authors:  L Feller; R A G Khammissa; J Fourie; M Bouckaert; J Lemmer
Journal:  Pain Res Treat       Date:  2017-12-05

Review 3.  Classification of Trigeminal Autonomic Cephalalgia: What has Changed in International Classification of Headache Disorders-3 Beta?

Authors:  K Ravishankar
Journal:  Ann Indian Acad Neurol       Date:  2018-04       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.